ALT - CIK 0001326190
The table below shows Altimmune, Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $43.76M | $36.93M | $135.12M | $111.10M | $190.30M | $115.92M |
| Short-term investments | $229.70M | $94.97M | $62.70M | $73.78M | $100.01M | $100.01M |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $278.19M |
| $137.25M |
| $209.63M |
| $192.81M |
| $204.13M |
| $230.26M |
| Property, plant & equipment | $312.00K | $413.00K | $651.00K | $1.08M | $1.45M | $1.06M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $279.93M | $139.31M | $210.64M | $206.93M | $218.86M | $245.12M |
| Accounts payable | $2.72M | $211.00K | $2.07M | $4.80M | $2.03M | $612.29K |
| Total current liabilities | $15.00M | $10.47M | $12.14M | $17.05M | $18.28M | $12.02M |
| Long-term debt | $34.29M | - | - | $4.58M | $1.45M | $1.83M |
| Total liabilities | $55.04M | $15.80M | $16.54M | $21.64M | $19.73M | $19.24M |
| Retained earnings | -$649.48M | -$561.39M | -$466.33M | -$377.88M | -$293.17M | -$186.42M |
| Total equity | $224.89M | $123.51M | $194.10M | $185.29M | $199.13M | $225.88M |